雷贝拉唑联合气滞胃痛颗粒治疗慢性萎缩性胃炎患者的临床观察  

Effect of rabeprazole combined with Qizhi Weitong cranules on improvements of symptoms and levels of serum G-17, MOT and T lymphocyte subsets in patients with chronic atrophic gastritis

作　　者：刘小娟[1] 陈策[1] 张艳芳[1] 刘复娜[1] LIU Xiao-jun;CHEN Ce;ZHANG Yan-fang;LIU Fu-na(Gastroenterology Dept,General Hospital of North Petroleum Administration,Cangzhou 062552,China)

机构地区：[1]华北石油管理局总医院

出　　处：《中国临床医生杂志》2020年第2期156-159,共4页Chinese Journal For Clinicians

摘　　要：目的探讨雷贝拉唑联合气滞胃痛颗粒对慢性萎缩性胃炎(chronic atrophic gastritis,CAG)患者症状改善及血清胃动素及胃泌素-17、T细胞亚群水平的影响。方法选取华北石油管理局总医院2015年11月至2017年5月CAG患者68例,按照随机数字表法分为对照组与研究组各34例。对照组采取雷贝拉唑,研究组采取雷贝拉唑^+气滞胃痛颗粒,两组均治疗3个月。统计两组症状(纳差、恶心、腹胀、嗳气、上腹痛)改善情况、临床疗效、治疗前后血清胃动素、胃泌素-17、T细胞亚群指标(CD4^+、CD8^+、CD4^+/CD8^+)水平及不良反应。结果治疗后两组纳差、恶心、腹胀、嗳气、上腹痛分值较治疗前降低,且研究组低于对照组(P<0.05);研究组总有效率(94.12%)较对照组(73.53%)高(P<0.05);治疗后两组血清胃动素、胃泌素-17水平较治疗前增高,且研究组高于对照组(P<0.05);治疗后两组CD4^+、CD4^+/CD8^+水平较治疗前增高,CD8^+水平较治疗前降低,且研究组CD4^+、CD4^+/CD8^+水平高于对照组,CD8^+水平低于对照组(P<0.05);研究组不良反应发生率(17.65%)与对照组(11.76%)比较差异无显著性(P>0.05)。结论联合采取雷贝拉唑及气滞胃痛颗粒治疗慢性萎缩性胃炎可有效缓解患者临床症状,增加血清胃动素、胃泌素-17含量,提高治疗效果,改善机体免疫功能,且不良反应较少,具有安全性。Objective To investigate the effect of rabeprazole combined with Qizhi Weitong granules on improvements of symptoms and levels of serum motilin(MOT), gastrin-17(G-17) and T lymphocyte subsets in patients with chronic atrophic gastritis(CAG). Method A total of 68 cases of CAG patients from November 2015 to May 2017 in our hospital were randomly divided into control group 34 and study group 34. The control group was treated with rabeprazole, and the study group was treated with rabeprazole ^+ Qizhi Weitong granules. Both groups were treated for 3 months. The improvement of symptoms(anorexia, nausea, abdominal distension, belching and abdominal pain), clinical efficacy, serum levels of MOT, G-17 and T lymphocyte subsets(CD4^+, CD8^+, CD4^+/CD8^+) before and after treatment and adverse reactions were observed in the two groups. Result The scores of anorexia, nausea, abdominal distension, belching and abdominal pain of the two groups after treatment were lower than those before treatment, and the study group was lower than the control group(P<0.05). The total effective rate of the study group(94.12%) was higher than that of the control group(73.53%)(P<0.05). After treatment, the levels of serum MOT and G-17 in the two groups were higher than those before treatment, and the study group was higher than the control group(P<0.05). After treatment, the levels of CD4^+ and CD4^+/CD8^+ in two groups were higher than those before treatment, and the level of CD8^+ was lower than that before treatment;the levels of CD4^+ and CD4^+/CD8^+ in study group was higher than those in control group, and the level of CD8^+ was lower than that in control group(P<0.05). The incidence of adverse reactions in the study group(17.65%) was not significantly different from that in the control group(11.76%)(P>0.05). Conclusion Rabeprazole combined with Qizhi Weitong granules in the treatment of patients with chronic atrophic gastritis could effectively relieve the clinical symptoms, increased the serum levels of MOT and G-17, improved the therape

关 键 词：雷贝拉唑 气滞胃痛颗粒 慢性萎缩性胃炎 胃泌素-17 胃动素 T细胞亚群 

分 类 号：R573[医药卫生—消化系统]